Physician profile
Sandeep Bhatia
NPI 1003034927
$4,709.15
in general payments reported to CMS, 2019-2025
22 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $201 · 2021: $518 · 2022: $353 · 2023: $857 · 2024: $1,201 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.33 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $843.60 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Biotissue Holdings INC. | $757.30 | 2020-2025 | |
| Abbvie INC. | $544.66 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Amgen INC. | $528.02 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $427.56 | 2023-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Sight Sciences, INC. | $319.47 | 2019-2021 | |
| Glaukos Corporation | $190.35 | 2019-2024 | Idose |
| Allergan, INC. | $163.24 | 2019-2021 | |
| Horizon Therapeutics Plc | $149.82 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $119.43 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $110.95 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $92.83 | 2019-2022 | |
| Rxsight INC | $87.55 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.84 | 2021 | |
| Bausch & Lomb Americas INC. | $76.76 | 2023-2025 | Vyzulta, Xiidra, Miebo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $56.02 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $48.79 | 2020-2024 | |
| Ocular Therapeutix, INC. | $41.38 | 2024-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $32.35 | 2019-2020 | |
| Vantage Technology LLC | $15.11 | 2023 | |
| Coopervision INC. | $13.59 | 2020 | |
| Lensar, INC. | $9.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.